WO2009025782A2 - Composition d'agent hémostatique et procédé d'administration - Google Patents

Composition d'agent hémostatique et procédé d'administration Download PDF

Info

Publication number
WO2009025782A2
WO2009025782A2 PCT/US2008/009830 US2008009830W WO2009025782A2 WO 2009025782 A2 WO2009025782 A2 WO 2009025782A2 US 2008009830 W US2008009830 W US 2008009830W WO 2009025782 A2 WO2009025782 A2 WO 2009025782A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
wound
hemostatic agent
site
hemostatic
Prior art date
Application number
PCT/US2008/009830
Other languages
English (en)
Other versions
WO2009025782A3 (fr
Inventor
Jack Mentkow
Lisa Mentkow
Original Assignee
Jack Mentkow
Lisa Mentkow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/191,323 external-priority patent/US8409629B2/en
Application filed by Jack Mentkow, Lisa Mentkow filed Critical Jack Mentkow
Priority to BRPI0817049 priority Critical patent/BRPI0817049A2/pt
Priority to MX2010001820A priority patent/MX2010001820A/es
Priority to CN200880103237A priority patent/CN101778623A/zh
Priority to CA2696400A priority patent/CA2696400A1/fr
Priority to EP08795409A priority patent/EP2197422A2/fr
Priority to AU2008289571A priority patent/AU2008289571A1/en
Priority to JP2010521051A priority patent/JP2010536762A/ja
Publication of WO2009025782A2 publication Critical patent/WO2009025782A2/fr
Publication of WO2009025782A3 publication Critical patent/WO2009025782A3/fr
Priority to ZA2010/01845A priority patent/ZA201001845B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Definitions

  • the present invention is directed to a hemostatic agent delivery composition and system.
  • the composition comprises a hectorite clay and an acceptable carrier composition.
  • One delivery system comprises a delivery assembly having a pouch or receptacle containing a hemostatic agent, the pouch being at least partially defined by a support member in combination with an overlying release member made of a soluble material.
  • the hemostatic agent delivery system is structured such that a hemostatic agent is delivered directly to a source of bleeding, and wherein the hemostatic agent is concentrated and retained at the bleeding source to facilitate clotting and terminate hemorrhaging.
  • Another delivery system comprises a syringe or ejection device containing the composition.
  • the composition may be applied from the syringe directly to a wound site, or may be directed by a catheter, tubing and the like into or near a hemorrhage site.
  • One such product comprises a granular zeolite material which may be obtained from volcanic lava rocks. This material is placed into a bleeding wound where it absorbs water molecules from the blood, thereby creating a high platelet concentration which promotes clotting.
  • this zeolite is a highly exothermic reaction which generates a considerable amount of heat, attributable to reaction with the iron content of the zeolite. More specifically, temperatures ranging from 9O 0 C to 100 0 C have been reported following use of the material, causing second degree burns to soldiers injured and treated with this product in Iraq, as well as to those persons administering the product, even though personnel administering this product must be trained and certified to administer the same.
  • a further drawback to this product is that the zeolite material is packaged to be simply poured on to an open wound, however, in the case of hemorrhaging of any significance, such as may occur due to laceration of a major artery, the pressure of blood exiting the wound will simply cause the material to be dispersed thereby minimizing and/or eliminating the effectiveness of the clotting properties therein.
  • Another disadvantage is that the zeolite's efficacy is exhausted at first contact with blood such that a clot may be formed distant to the actual wound source without stopping hemorrhaging.
  • zeolite material is granular in nature, making it difficult to subsequently remove the material from the wound via normal means such as irrigation and/or suctioning of the wound area, once the injured person is transferred to an operating room or other such treatment facility.
  • Another product is made from chitosan, which is derived from the exoskeletons of shellfish. Reports as to the effectiveness of this device in hemorrhage control are conflicting, in particular, its effectiveness in the event of hypothermia in the patient, such as may occur from shock following significant blood loss, is reported to be severely reduced or diminished. In addition, there have been reports of the device being improperly applied, e.g., the wound is not contacted by the active surface due to the device being placed into the wound site upside down. Since this product is derived from living organisms, it has an extremely limited shelf life during which time it must either be utilized or disposed of, and given the significant cost of each unit, this is a further considerable disadvantage.
  • Another type of hemostatic bandage is manufactured from single cell algae and comprises poly-N-acetylglucosamine.
  • This device is structured to enable persons with minimal training to quickly and effectively control and/or stop hemorrhaging from extremity trauma. More in particular, when the material comes in contact with blood it reportedly stimulates platelet aggregation and activation which causes the body to secrete tromboxane, which stimulates the blood vessels to constrict in the vicinity of the wound. Stated differently, the poly-N-acetylglucosamine material acts as a catalyst to accelerate the normal clotting process thereby accelerating the bodies' own control of the bleeding. Once again, since this product is derived from living organisms, it has a limited shelf life during which it must be utilized or disposed.
  • this material is also in a powder form and has been applied directly to a bleeding wound with a bellows type applicator as noted above with respect to the zeolite material, however, in the event of excessive bleeding such as a major artery, the pressure of the blood flowing from the wound is often sufficient to disperse the powder thereby once again, minimizing or eliminating the clotting property exhibited therein, even though the wound site is to be covered with a standard bandage and pressure applied after treatment with the synthesized potato starch material.
  • Yet another powdered material is composed from a hydrophilic polymer and a potassium salt in combination with a bovine based thrombin material.
  • TraumaCure Bethesda, MD
  • TraumaCure One product patented from TraumaCure (Bethesda, MD) is a balloon device. A deflated balloon is inserted through the wound entry point and then inflated while in the wound cavity, putting pressure against the wound walls and source of bleeding.
  • hemostatic agent employed in such a system should promote clotting of the blood in a non- reactive manner, i.e., without exothermic reaction with the blood and the localized temperature increase associated therewith.
  • Yet another advantage may be realized by providing such a system with a hemostatic agent which is inorganic, thereby benefiting from an essentially indefinite shelf life.
  • the present invention is directed to a hemostatic agent composition and delivery systems which are structured to deliver a hemostatic agent composition directly to a hemorrhage site, for example, a lacerated artery, so as to facilitate clotting of the blood and terminate hemorrhaging at the site.
  • the hemostatic agent delivery system of the present invention is further structured to concentrate and retain the hemostatic agent at the hemorrhage site, once again, to facilitate clotting and terminate hemorrhaging.
  • the composition of the present invention is easily and economically manufactured and priced accordingly, affording the consumer and general public greater access to these life saving inventions.
  • At least one embodiment of the delivery system of the present invention includes at least one hemostatic agent composition structured to facilitate blood clotting. More in particular, at least one hemostatic agent of the present invention comprises a smectite clay material. In at least one further embodiment, a hectorite clay is utilized as the hemostatic agent.
  • the present invention encompasses the utilization of a clay material as a hemostatic agent either alone or in combination with one or more additives, as is discussed further below.
  • the delivery system of the present invention further comprises a delivery assembly which is structured to at least temporarily contain an amount of the hemostatic agent, at least until the agent is delivered proximate to a hemorrhage site.
  • the delivery assembly in at least one embodiment, includes a release member disposed in overlying relation to a support member. More in particular, the release member and the support member are cooperatively structured to at least temporarily contain the hemostatic agent therebetween, the release member and the support member being attached about their respective peripheries.
  • the release member comprises a soluble material structured to at least partially dissolve and release the hemostatic agent upon disposition directly proximate to a hemorrhage site.
  • the release member comprises a soluble polymeric material, such as, by way of example only, a polyvinyl alcohol material.
  • the delivery assembly of the present invention may also include a handle member attached to an outer surface of the support member, wherein the handle member is structured to facilitate handling of the delivery system by a user.
  • a handle member having a visual indication to facilitate location or identification of the handle member by a user. This feature may prove critical in the hectic and often chaotic environment in which the hemostatic delivery system of the present invention is utilized, such as, on the battle field, field medical unit, or hospital emergency room.
  • the present invention further encompasses a method of application of a hemostatic agent to a hemorrhage site including the step of delivery of an amount of a hemostatic agent, wherein the hemostatic agent comprises a beneficiated hectorite clay material, directly proximate the hemorrhage site.
  • the method further includes concentrating the amount of hemostatic agent in a substantially conforming relation to the configuration of the hemorrhage site, and retaining the amount of the hemostatic agent at the hemorrhage site in a substantially occluding relation so as to facilitate clotting and terminate hemorrhaging at the site.
  • the method further provides for removing the hemostatic agent from the hemorrhage site via standard irrigation and suction procedures, once a patient has been stabilized and transferred, for example, to a fixed facility operating room or field operating unit.
  • the hemostatic agent of the present invention is structured to form a stable clot such that the patient may be moved, once hemorrhaging has been effected.
  • FIG. 1 is a perspective view of one preferred embodiment of a hemostatic agent delivery system in accordance with the present invention.
  • FIG. 2 is a partially exploded view of the embodiment of FIG. 1.
  • FIG. 3 is a diagrammatic representation of a method of application of a hemostatic agent in accordance with the present invention.
  • Like reference numerals refer to like parts throughout the several views of the drawings.
  • the present invention is directed to a hemostatic agent delivery system, generally as shown as 10 in the figures, which is structured to facilitate delivery of a hemostatic agent directly proximate a hemorrhage site. More in particular, the present invention is directed towards a hemostatic agent delivery system 10 which may be quickly and effectively utilized to facilitate clotting and to control and/or terminate hemorrhaging of an injured person, such as, a soldier wounded on a battle field, by personnel with minimal training. As will become apparent from the following, the hemostatic agent delivery system 10 of the present invention is structured such that personnel with minimal instruction in its use will be able to readily identify the proper orientation of the delivery assembly 20, so as to facilitate disposition of the delivery assembly 20 directly proximate a hemorrhage site.
  • the hemostatic agent delivery system 10 of the present invention comprises at least one hemostatic agent 12.
  • the hemostatic agent 12 of the present invention in at least one embodiment, comprises a hydroxyethyl cellulous additive structured to enhance the absorption of water from the blood by the hemostatic agent 12, thereby increasing the rate of clot formation, and termination of the hemorrhage.
  • bleeding is a major cause of death in both military and civilian injuries, and the present invention enables quick and effective control and/or termination of hemorrhaging, which is proven to save lives.
  • At least one hemostatic agent 12 comprises smectite clay.
  • Smectite is a family of naturally occurring layered swelling clays which include bentonite, also known as montmorillonite, hectorite, and saponite. Kaolinite, a related clay, is less absorbent and swelling than the aforementioned. More in particular, the smectite clays are layered silicates which swell in water, and are widely used as rheological additives. Specifically, the silicate platelets comprise three layers, two silicate dioxide layers which embed a metal oxide layer. In bentonite clays, the metal oxide layer is mainly aluminum, whereas in hectorite clay the metal oxide layer comprises magnesium.
  • bentonite may include approximately 4% by weight of ferric and ferrous oxides
  • hectorite clay is essentially iron free, comprising generally less than one-half of one percent ( ⁇ 0.50%) by weight. This is important, as a presence of iron is believed to promote exothermic reactions between hemostatic agents and body fluids during absorption processes.
  • a further benefit of hectorite clay, for use in conjunction with the present invention, is that it can be highly beneficiated, i.e., purified and ground, such that the particle size of hectorite clay is approximately 10% that of similar bentonite clays.
  • One preferred embodiment of the present invention comprises a beneficiated hectorite clay as a hemostatic agent 12. More in particular, the present invention may comprise Bentone EW. RTM.
  • Bentone EW. RTM which is a highly beneficiated hectorite clay available from Elementis Specialties of Hightstown N.J. Bentone EW. RTM. has a density of about 2.5 grams per cubic centimeters (g/cm.sup.3) and, more importantly, a particle size distribution wherein approximately 94% or greater of the material is less than 200 mesh screen size.
  • the present invention comprises a hemostatic agent delivery system 10 comprising a plurality of hemostatic agents 12, as one example, at least one embodiment may comprise bentonite clay, or a combination of hectorite and bentonite clays in a variety of proportions. Also as noted above, one or more additives may be combined with the hemostatic agent 12 to enhance the hemostatic properties thereof.
  • the hemostatic agent 12 comprises a highly beneficiated hectorite clay in combination with a hydroxyethyl cellulous additives. More in particular, the hemostatic agent 12 of one preferred embodiment comprises Bentone LT. RTM. once again, available from Elementis Specialties.
  • the hemostatic agent 12 be essentially inert and non-reactive when disposed in contact with an open wound, and the blood or other body fluids being released therefrom.
  • the hectorite clays do not include iron components to any significant degree therefore they are essentially non exothermic upon contact with water, blood, or other aqueous or bodily fluids.
  • the powdered physical configuration of beneficiated hectorite clay it serves to aid in the formation of a stable clot upon application to a hemorrhage site. Specifically, Bentone EW. RTM.
  • the hemostatic delivery system 10 of the present invention further comprises a delivery assembly 20 which is structured to facilitate disposition of an amount of a hemostatic agent 12 directly proximate a hemorrhage site.
  • the delivery assembly is structured to releasably contain an amount of the hemostatic agent 12 for delivery to a hemorrhage site.
  • the delivery assembly 20 includes a release member 24 which is disposed in overlying relation to an oppositely disposed support member 22, the release member being attached to and about a periphery of the support member 22.
  • the release member 24 and the support member 22 are cooperatively structured so as to at least temporarily contain the amount of hemostatic agent 12 for delivery to a hemorrhage site, as illustrated in FIG. 1.
  • the support member 22 comprises a sterile dressing, such as, by way of example, an anti-stick gauze pad.
  • a sterile dressing such as, by way of example, an anti-stick gauze pad.
  • the release member 24 comprises a soluble material of construction which is structured to at least partially dissolve upon contact with an aqueous solution, such as blood discharging from a wound. Upon dissolving, the release member 24 of the present invention will release the amount of hemostatic agent 12 from the delivery assembly 20 directly proximate to the hemorrhage site in a rapid and effective manner.
  • the delivery assembly 20 of the present invention comprises a release member 22 constructed of the soluble polymeric material which is structured to dissolve in blood and body fluids therewith.
  • the release member 22 comprises a polyvinyl alcohol material which will substantially dissolve upon contact with blood at a hemorrhage site.
  • the polyvinyl alcohol material of the release member 22 may be constructed of any of a variety of thicknesses, thereby controlling the rate at which the release member 22 will dissolve and, as such, the rate at which the hemostatic agent 12 will be delivered to a hemorrhage site, a factor which is also affected by the volume of fluid present.
  • the hemostatic agent delivery system 10 of the present invention may be customized for application to a variety of wounds of varying degrees of severity.
  • the hemostatic agent 12 may be applied directly proximate a superficial wound, in which case, the release member 22 will preferably comprise a very thin material so as to permit rapid dissolution and release of the hemostatic agent 12.
  • the release member 22 will comprise a greater thickness, to assure that the hemostatic agent delivery system 10 may be disposed proximate the hemorrhage site and configured to substantially conform to the wound prior to dissolution of the release member 24 and subsequent release of the hemostatic agent 12 to the hemorrhage site.
  • the delivery assembly 20 of the present invention further comprises a seal mechanism 27 structured to facilitate attachment between the members.
  • the seal mechanism 27 of the present invention comprises at least one seal member 28 which is structured to hermetically seal the release member 24 to the support member 22.
  • the seal member 28 comprises a heat reactive adhesive.
  • the seal member 28 comprises an iron-on adhesive.
  • the seal member 28 of this embodiment is structured to bond two dissimilar materials, each of which independently are structured to be non-adhesive, thereby forming a hermetically sealed pouch 21 which releasably contains one or more hemostatic agent 12.
  • the delivery assembly 20 of the present invention further comprises a handle member 29, as illustrated in the figures.
  • the handle member 29, serves several purposes, the first of which being to facilitate disposition of the delivery assembly 20 directly proximate to a hemorrhage site to facilitate delivery of a hemostatic agent thereto. More in particular, the handle member 29 is structured and configured to be grasped by one hand of a user and allow the user to quickly and effectively direct the surface of the delivery assembly 20 comprising the release member 24 directly onto a hemorrhage site, such as, a lacerated artery. As seen in FIGS.
  • the handle member 29 is attached to an outer face of support member 22 and disposed opposite the outer surface of the release member 24, and as such, the handle member 29 allows for the user to grasp the delivery assembly 20 with hands that may be wet or bloody, yet hindering contact with the release member 24, so as to prevent inadvertent and premature release of the hemostatic agent 12.
  • the handle member comprises a visual indication 29, to facilitate location of the handle member 29 by a user.
  • the visual indication 29' may include indicia such as letters, symbols, stripes, etc., applied directly onto the handle member 29 as shown in FIG. 2.
  • the visual indication 29' may comprise a color contrast between the support member 22, typically being a white color sterile gauze pad, and the handle member 29, which may comprise a bright color or color pattern, for example, a striped pattern as illustrated in FIG. 2.
  • the present invention further comprises a method for application of a hemostatic agent to a hemorrhage site, generally as illustrated at 100 in FIG. 3. More in particular, the method 100 of the present invention comprises delivering 110 an amount of a hemostatic agent comprising a beneficiated hectorite directly proximate a hemorrhage site. The method 100 further comprises concentrating 120 the amount of the hemostatic agent in a substantially conforming relation to the configuration of the hemorrhage site, and retaining 130 the amount of the hemostatic agent at the hemorrhage site in a substantially occluding relation to the hemorrhage site so as to facilitate clotting and terminate hemorrhaging therefrom.
  • the method 100 of the present invention further comprises the step of removing 140 the amount of the hemostatic agent from the hemorrhage site via irrigation and suction, once a patient is stabilized, for example, upon transference to a field hospital or an emergency room.
  • compositions that is delivered to a wound that has the ability to assist in blood clotting both in the wound where the composition is applied, and will travel in the body or wound track to assist in the clotting of other wounds.
  • the first column is a number identifying the formulation.
  • a legend appears after the chart that details the components used in the various formulations.
  • Table 2 represents an evaluation of each formulation number in terms of relative consistency and separation stability.
  • Formulation 48 - Final Formulation Tested 3x Freeze/Thaw cycle, and 3xl50°F, 3 months@ ⁇ 75°F, no separation. Tested absorption rate. Observed excellent absorption with more than eight times liquid volume absorption in ⁇ 1 minute.
  • composition demonstrated stability from 32 0 F - 15O 0 F.
  • a composition based on formulation 48 was tested as set forth below.
  • a small amount of a composition of formula 48 was tested for a determination of the adhesive strength of the product at four coating thicknesses.
  • a small spring type tensiometer (Hunter Spring brand) was connected to small wooden blocks having two smooth surfaces (each 2.25 sq.in) to be coated with the composition. The test would determine the pull strength (psi) required to cause the composition to fail.
  • the hemostatic composition shows good adhesion (greater than 1 pound per square inch) for very thin coatings between two wooden test surfaces.
  • the adhesion drops to 0.542 psi.
  • a composition according to formula 48 tested kinematic viscosity at room temperature (25 0 C ) using a Brookfield Viscometer, Model No. RVF.
  • the intention for the first application was to apply the product to a femoral bleed caused by a puncture type wound with a small skin opening in a swine to simulate a stabbing or shrapnel type of injury.
  • An incision on the skin of approximately 2cm in length was made.
  • a scalpel was inserted through the skin where a strong venus flow was achieved.
  • One 60cc syringe full of the hemostatic agent composition was applied to the wound and it was able to stop the bleeding within 3 minutes.
  • the second test was performed on a ballistic wound track from a shotgun discharge.
  • the subject in particular had already received a wound to the outside of the rump which had torn the skin open with some underlying tissue damage from a previous wounding phase.
  • the wound created for the test of the product was a shotgun blast using a special round which is commonly used by SWAT teams to blast the locks of doors to gain entry into buildings.
  • the shotgun was placed approximately six inches away from the skin. The blast left a hole about the size of a nickel with burn marks around the wound entrance. After about 5 seconds the blood began to appear at the site of the wound.
  • Two 60cc syringes of the hemostatic composition were applied inside the wound track and direct pressure was applied over the wound. After 5 minutes of direct pressure the bleeding was under control.
  • the wound was examined to visualize the damage of the shotgun blast and the efficacy of the product.
  • One Yorkshire swine ( ⁇ 82 kg) was anesthetized with an intramuscular Telazol (ketamine and Valium 30mg/kg) .
  • An endotracheal tube was inserted in addition to an IV line placed in a left external jugular vein using a surgical cut down technique. Patency of the IV line was maintained with an initial saline bolus flush. The IV saline was frequently flushed following IV drug administration.
  • the veterinary staff monitored the animal to maintain sedation along with pain management throughout the 180 minutes.
  • the swine was lifted back on an army litter and carried 200 yards down a slight uneven grade back to the training area without rebleeding and placed under a tent where the animal was covered with an impermeable plastic wrap to prevent heat loss and was monitored for approximately additional 120 minutes.
  • Vital signs HR, RR, SpO2, rectal temp
  • HR, RR, SpO2, rectal temp were continuously recorded every thirty minutes from point of injury along with all drug administered by the veterinary staff. At no time in this prolonged care phase did either wound site continue to bleed.
  • the formulation comprises:
  • composition is prepared by:
  • the resulting mixture has a viscosity of more than 50,000 CPs.
  • the pH of the composition is 7.68 and the specific gravity is 1.2773. This specific gravity has the added benefit of preventing dispersion of the mixture even against major arterial bleeding.
  • a preferred hectorite has a particle size of 95% less than 0.076mm (less than 76 ⁇ m, or 76 microns) .
  • An advantage of the present invention is the composition does not interfere with the chemical-physiological processes of the coagulation process. That is to say, the chemical, physical, and physiological processes of both intrinsic and extrinsic blood coagulation mechanism are not affected by the hemostatic composition of the present invention.
  • composition absorbs up to eight times its weight of water in less than one minute.
  • concentration of blood platelets and coagulation proteins are increased and results in the composition having an increased ability to accelerate and maintain blood clots.
  • the propylene glycol in the composition is a humectant and helps impart upon the composition a hydrophilic matrix that provides increased and accelerated absorption through the various layers.
  • composition itself presented a problem in providing a suitable liquid carrier to deliver the clay to a wound that would not itself cause the clay to swell thereby negating its hemostatic properties of absorption prior to application.
  • composition formulation of the present invention has successfully addressed and solved this difficulty by preparing a stable viscous liquid carrier composition that will deliver the clay to a wound site without causing the clay to reduce its water absorption capacity.
  • the percentage of water in the formulation used to promote the dispersal of the suspension agent is offset many times over by the benefits of the addition of the humectant, propylene glycol.
  • an optimal water percentage of less than about 10% is relatively small, yet does not affect the stability of the composition.
  • composition of the present invention would be efficacious in assisting clotting in both extrinsic and intrinsic sites.
  • a ballistic wound may create more than one bleeding source in the same wound track in need of clotting.
  • the composition of the present invention will simultaneously assist the clotting in each of the external and internal wounds.
  • the ability to assist in clotting multiple wounds from a single administered site is important as indirect wound tracks are most often difficult to access using current technology and treatment procedures.
  • the assist in clotting using the composition of the present invention will occur with or without an exit wound being present at the hemorrhage site or sites to which the composition has traveled.
  • the composition has an increased elasticity that allows it to conform to a particular shape at a wound site.
  • due to this elasticity factor the clot remains stable and will not rupture.
  • composition has an elevated viscosity, it has been observed that the viscosity and adhesion qualities of the composition do not hinder subsequent removal after a blood clot has formed.
  • the composition may be removed as desired by conventional wound irrigation techniques. These wound irrigation techniques are sufficient to remove the composition once it is observed that blood flow has substantially decreased and or/stopped.
  • the composition may absorb up to twenty four times its weight in water.
  • the absorption is noteworthy because the composition already contains water.
  • the composition is able to absorb, in one embodiment, up to twenty four times its weight in water, and in a preferred embodiment, up to eight times its weight in water in less than about one minute, even though the composition as provided may comprise up to about ten percent water. This becomes imperative in cases of major arterial bleeding, especially in hot or dry climates when a wound is being treated, as a patient may often be in need of hydration. Conventional treatment procedures and protocols do not provide for the administration of fluids to patients with major arterial bleeding.
  • the composition of the present invention not only provides rapid and critical assistance in the blood clotting process, but allows for the administration of fluids, which may also be critical to the survival of a patient while not interrupting or disturbing the therapeutic effect of the administered composition.
  • patients with traumatic wounds do not receive fluids until they reach the operating theatre for fear that the accompanying elevated blood pressure will cause rebleeding.
  • the present composition has demonstrated the proper adhesive strength such that it remains in contact with tissue at and/or near a wound site in spite of a buildup of hydrostatic pressure from bleeding. This adhesion affords the composition sufficient contact time to promote clotting, even in cases of major arterial bleeding.
  • This adhesive property provides an additional benefit in that using the composition of the present invention does not require pressure to be applied in order to facilitate a blood clot.
  • the composition of the present invention is contained within a syringe or ejection device.
  • the syringe may be used to apply the composition directly to a wound.
  • the syringe may further have a catheter, tubing or other directional means affixed thereto for directing the application of the composition to a wound.
  • the syringe or ejection delivery offers many advantages.
  • a syringe may deliver the composition through a narrow opening. Even if one cannot see the actual hemorrhage site, the composition may be introduced through an opening believed to be close to a hemorrhage site.
  • the hemorrhage is internal and an entry point in the skin from an object, such as a bullet, shrapnel and the like, may be used to administer the composition. Thus, treatment may occur even if the hemorrhage site cannot be seen.
  • the composition will travel internally to a hemorrhage site. There is no need to evacuate blood from a wound and, in using a syringe, there is no need to enlarge a wound site causing additional trauma in order to administer the composition.
  • a patient may be able to self-administer the composition.
  • the composition may also be administered holding the syringe in one hand.
  • the single handed administration may be important in self administration.
  • Many current protocols and procedures require wound enlargement, blood evacuation, and application by more than one medical care giver in some cases which is not required using this delivery system.
  • a further advantage of the syringe delivery is that it does not require any special training to administer. Most other wound treatments currently in use require extensive medical training to administer and may not be self-administrable.
  • the composition of the present invention also provided the advantageous feature that it does not require pressure be applied in order to facilitate a clot.
  • the composition may be incorporated into a patch.
  • patch delivered therapeutic compositions are contained within the patch by a film of polyvinyl alcohol (PVA) .
  • PVA film dissolves when in contact with water or liquid thus dispensing the active ingredient contained therein.
  • the composition of the present invention is formulated in an aqueous carrier for delivering the hectorite clay to a wound site. It is typically not desirable to utilize aqueous systems in patch delivery where PVA films are used.
  • the propylene glycol of the present composition is a humectant and the present composition formulation has demonstrated that the small percentage of water in the formulation is bound to it and will not leach out while in contact with the PVA to prematurely dissolve the film.
  • PVA is additionally advantageous because, in the area not immediately proximate to the hemorrhage site, PVA adheres to the surrounding tissue providing additional occlusion, aiding the retention of the hemostatic agent, and promoting increased efficacy of the hemostatic agent of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition d'agent hémostatique qui comprend un agent hémostatique à base d'argile qui est inerte et non réactif par rapport aux protéines de la coagulation sanguine et aux plaquettes, et qui est pourtant capable d'accélérer la formation d'un caillot stable lorsqu'il est appliqué sur une plaie saignant activement.
PCT/US2008/009830 2007-08-16 2008-08-18 Composition d'agent hémostatique et procédé d'administration WO2009025782A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0817049 BRPI0817049A2 (pt) 2007-08-16 2008-08-18 Composições e método de aplicação de agente hemostático
MX2010001820A MX2010001820A (es) 2007-08-16 2008-08-18 Composicion de un agente hemostatico y su metodo de aplicacion.
CN200880103237A CN101778623A (zh) 2007-08-16 2008-08-18 止血剂组合物及施加方法
CA2696400A CA2696400A1 (fr) 2007-08-16 2008-08-18 Composition d'agent hemostatique et procede d'administration
EP08795409A EP2197422A2 (fr) 2007-08-16 2008-08-18 Composition d'agent hémostatique et procédé d'administration
AU2008289571A AU2008289571A1 (en) 2007-08-16 2008-08-18 Hemostatic agent composition and method of delivery
JP2010521051A JP2010536762A (ja) 2007-08-16 2008-08-18 止血剤組成物および供給方法
ZA2010/01845A ZA201001845B (en) 2007-08-16 2010-03-16 Hemostatic agent composition and method of delivery

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96495507P 2007-08-16 2007-08-16
US60/964,955 2007-08-16
US12/191,323 US8409629B2 (en) 2006-01-09 2008-08-14 Hemostatic agent composition and method of delivery
US12/191,323 2008-08-14

Publications (2)

Publication Number Publication Date
WO2009025782A2 true WO2009025782A2 (fr) 2009-02-26
WO2009025782A3 WO2009025782A3 (fr) 2009-04-09

Family

ID=40378868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009830 WO2009025782A2 (fr) 2007-08-16 2008-08-18 Composition d'agent hémostatique et procédé d'administration

Country Status (10)

Country Link
EP (1) EP2197422A2 (fr)
JP (1) JP2010536762A (fr)
CN (1) CN101778623A (fr)
AU (1) AU2008289571A1 (fr)
BR (1) BRPI0817049A2 (fr)
CA (1) CA2696400A1 (fr)
MX (1) MX2010001820A (fr)
RU (1) RU2010109699A (fr)
WO (1) WO2009025782A2 (fr)
ZA (1) ZA201001845B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL254644B (en) * 2017-09-24 2021-06-30 Reddress Ltd Device for dressing a wound, system and method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060015235A1 (en) * 2004-07-15 2006-01-19 Ringger Kurt A Common control interface for diverse automated manual transmissions
WO2006088912A2 (fr) * 2005-02-15 2006-08-24 Virginia Commonwealth University Technologies minerales pour une hemostase aigue et pour le traitement de lesions aigues et d'ulceres chroniques
WO2007081760A2 (fr) * 2006-01-09 2007-07-19 Jack Mentkow Système d’administration d’agent hémostatique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060015235A1 (en) * 2004-07-15 2006-01-19 Ringger Kurt A Common control interface for diverse automated manual transmissions
WO2006088912A2 (fr) * 2005-02-15 2006-08-24 Virginia Commonwealth University Technologies minerales pour une hemostase aigue et pour le traitement de lesions aigues et d'ulceres chroniques
WO2007081760A2 (fr) * 2006-01-09 2007-07-19 Jack Mentkow Système d’administration d’agent hémostatique

Also Published As

Publication number Publication date
AU2008289571A1 (en) 2009-02-26
RU2010109699A (ru) 2011-09-27
WO2009025782A3 (fr) 2009-04-09
CA2696400A1 (fr) 2009-02-16
MX2010001820A (es) 2010-06-02
CN101778623A (zh) 2010-07-14
JP2010536762A (ja) 2010-12-02
BRPI0817049A2 (pt) 2015-03-24
ZA201001845B (en) 2011-02-23
EP2197422A2 (fr) 2010-06-23

Similar Documents

Publication Publication Date Title
US8409629B2 (en) Hemostatic agent composition and method of delivery
US8609129B2 (en) Hemostatic agent composition, delivery system and method
US9474652B2 (en) Hemostatic agent delivery system
EP2427157B1 (fr) Dispositifs et méthodes de lutte contre l'hémorragie
US7303759B2 (en) Compositions and methods for reducing blood and fluid loss from open wounds
Clay et al. Comparative testing of new hemostatic agents in a swine model of extremity arterial and venous hemorrhage
US9950091B2 (en) Composition and method for stopping hemorrhage, infection, and accelerating healing in various types of wound or burns
JP2005503197A (ja) 創傷被覆材、および重篤で生命にかかわる出血を制御する方法
CN101081308A (zh) 壳聚糖止血剂
JP6554474B2 (ja) ラップを含む外傷性創傷ドレッシングシステム
US20130022552A1 (en) Blood clotting composition and method of use
CN109689069A (zh) 具有止血作用的伤口覆盖物及其产生方法
EP2197422A2 (fr) Composition d'agent hémostatique et procédé d'administration
Burgert et al. Effects of arterial blood pressure on rebleeding using Celox and TraumaDEX in a porcine model of lethal femoral injury
RU2810584C1 (ru) Термоуправляемая композиция для временной остановки кровотечений
Xie et al. Comparison of Hemostatic Efficacy of ChitoGauze and Combat Gauze in a Lethal Femoral Arterial Injury in Swine Model
Ryan et al. Overview of the hemostasis research program: advances and future directions
Kheirabadi et al. Development of hemostatic dressings for use in military operations
CN114269350A (zh) 局部止血组合物
Marcus Catastrophic haemorrhage and emergency care
Champagne Serendipity, Super Glue and Surgery: Cyanoacrylates as Hemostatic Aids in the Vietnam War
Allison et al. Battlefield-Tested Hemostatic Agents: Their Applications for Hemorrhage Control in Hospital Settings Battlefield-Tested Hemostatic Agents: Their Applications for Hemorrhage Control in Hospital Settings

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880103237.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795409

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010521051

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2696400

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/001820

Country of ref document: MX

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008289571

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1346/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010109699

Country of ref document: RU

Ref document number: 2008795409

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2008289571

Country of ref document: AU

Date of ref document: 20080818

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: PI0817049

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100210